Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Parasitology ; 148(13): 1595-1601, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-35060468

RESUMO

The aim of the present work was to evaluate the distribution of the different clones of the parasite prevailing after treatment with benznidazole (BZ) and clomipramine (CLO), in mice infected with Trypanosoma cruzi, Casibla isolate which consists of a mixture of two discrete typing units (DTUs). Albino Swiss mice were infected and treated with high and low concentrations of BZ (100 or 6.25 mg/kg), CLO (5 or 1.25 mg/kg), or the combination of both low doses (BZ6.25 + CLO1.25), during the acute phase of experimental infection. Treatment efficacy was evaluated by comparing parasitaemia, survival and tissular parasite presence. For DTUs genotyping, blood, skeletal and cardiac muscle samples were analysed by multiplex quantitative polymerase chain reaction. The combined treatment had similar outcomes to BZ6.25; BZ100 was the most effective treatment, but it failed to reach parasite clearance and produced greater histological alterations. Non-treated mice and the ones treated with monotherapies showed both DTUs while BZ6.25 + CLO1.25 treated mice showed only TcVI parasites in all the tissues studied. These findings suggest that the treatment may modify the distribution of infecting DTUs in host tissues. Coinfection with T. cruzi clones belonging to different DTUs reveals a complex scenario for the treatment of Chagas disease and search for new therapies.


Assuntos
Doença de Chagas , Coinfecção , Trypanosoma cruzi , Animais , Doença de Chagas/tratamento farmacológico , Doença de Chagas/parasitologia , Combinação de Medicamentos , Genótipo , Camundongos , Distribuição Tecidual
2.
Mol Biochem Parasitol ; 222: 29-33, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29709547

RESUMO

In the present work, we evaluated the effect of mixed Trypanosoma cruzi infections, studying the biological distribution of the different parasites in blood, heart and skeletal muscle during the acute phase. Albino Swiss mice were infected with different parasite strain/isolates or with a combination of them. The parasites in the different tissues were typified through specific PCR, population variability was analyzed through RFLP studies and parasitological and histopathological parameters were evaluated. We found a predominance of TcII and TcVI in all tissues samples respect to TcV and different parasite populations were found in circulation and in the tissues from the same host. These results verify the distribution of parasites in host tissues from early stages of infection and show biological interactions among different genotypes and populations of T. cruzi.


Assuntos
Doença de Chagas/parasitologia , Trypanosoma cruzi/fisiologia , Animais , Doença de Chagas/sangue , Doença de Chagas/patologia , Feminino , Genótipo , Coração/parasitologia , Humanos , Masculino , Camundongos , Músculo Esquelético/parasitologia , Músculo Esquelético/patologia , Reação em Cadeia da Polimerase , Distribuição Tecidual , Trypanosoma cruzi/genética , Trypanosoma cruzi/crescimento & desenvolvimento
3.
Acta Trop ; 145: 79-87, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25733492

RESUMO

Thioridazine (TDZ) is a phenothiazine that has been shown to be one of the most potent phenothiazines to inhibit trypanothione reductase irreversibly. Trypanothione reductase is an essential enzyme for the survival of Trypanosoma cruzi in the host. Here, we reviewed the use of this drug for the treatment of T. cruzi experimental infection. In our laboratory, we have studied the effect of TDZ for the treatment of mice infected with different strains of T. cruzi and treated in the acute or in the chronic phases of the experimental infection, using two different schedules: TDZ at a dose of 80 mg/kg/day, for 3 days starting 1h after infection (acute phase), or TDZ 80 mg/kg/day for 12 days starting 180 days post infection (d.p.i.) (chronic phase). In our experience, the treatment of infected mice, in the acute or in the chronic phases of the infection, with TDZ led to a large reduction in the mortality rates and in the cardiac histological and electrocardiographical abnormalities, and modified the natural evolution of the experimental infection. These analyses reinforce the importance of treatment in the chronic phase to decrease, retard or stop the evolution to chagasic myocardiopathy. Other evidence leading to the use of this drug as a potential chemotherapeutic agent for Chagas disease treatment is also revised.


Assuntos
Doença de Chagas/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , NADH NADPH Oxirredutases/antagonistas & inibidores , Tioridazina/farmacologia , Animais , Relação Dose-Resposta a Droga , Camundongos , Trypanosoma cruzi/efeitos dos fármacos , Trypanosoma cruzi/enzimologia
4.
Acta Trop ; 133: 98-109, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24560963

RESUMO

We evaluated the presence and distribution of two Trypanosoma cruzi natural isolates in blood, heart, skeletal muscle, liver, and spleen tissues in the acute phase of the experimental infection (35 days postinfection) in order to determine if the populations present in blood were different to those found in the tissues of the same host. Thirty mice were infected with 50 forms of each isolate or with a combination of them. Presence and molecular characterization of the parasites in the host tissues were determined by specific PCR. Cardiac and skeletal muscle alterations were analyzed by histological studies. T. cruzi variability in the host tissues was analyzed through RFLP studies. Both isolates used consisted of a mixture of two T. cruzi lineages. Specific PCRs were positive for most of the samples from the 3 groups analyzed. Cardiac and skeletal muscle sections from the groups infected with one isolate presented mild to moderate inflammatory infiltrates; the group infected with both isolates showed severe inflammatory infiltrates and the presence of amastigote nests in both tissues. Different parasite populations were found in circulation and in the tissues from the same host. These results are important for patients with high probability of mixed infections in endemic areas and contribute to the knowledge of parasite/host interactions.


Assuntos
Sangue/parasitologia , Doença de Chagas/parasitologia , Variação Genética , Trypanosoma cruzi/classificação , Trypanosoma cruzi/isolamento & purificação , Animais , Doença de Chagas/patologia , DNA de Protozoário/genética , Modelos Animais de Doenças , Feminino , Genótipo , Masculino , Camundongos , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição , Trypanosoma cruzi/genética
5.
Parasitol Int ; 62(3): 293-9, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23500720

RESUMO

Alternative strategies are being designed to identify candidates among drugs already available on the market that could be used in combination to improve the efficacy of Chagas disease treatment. This work evaluates the effect of the association of clomipramine (CLO) with benznidazole (BZN) for the treatment of experimental Chagas disease in the acute stage, in Swiss albino mice infected with Trypanosoma cruzi Tulahuen strain. Infected mice were treated with CLO 5mg/kg/day and BZN 50 and 100mg/kg/day, each separately or together. Efficacy of the treatment was evaluated through parasitemia, survival, electrocardiography, histopathological studies, serological and PCR assays at 90 days post-infection (dpi). All treatments significantly (P<0.05) reduced mortality and decreased parasitemia. Histopathological analysis of liver and kidneys of mice treated with CLO and the drug combination showed less injury than mice treated only with BZN. The lower dose of BZN (50mg/kg/day) combined with CLO showed the same efficacy as the habitual dose of BZN (100mg/kg/day) combined with CLO. The therapeutic results from the combination of BZN with CLO presented lesser side effects than the treatment with BZN.


Assuntos
Doença de Chagas/tratamento farmacológico , Clomipramina/uso terapêutico , Nitroimidazóis/uso terapêutico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos , Animais , Doença de Chagas/patologia , Clomipramina/farmacologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Eletrocardiografia , Feminino , Intestinos/patologia , Rim/patologia , Fígado/patologia , Masculino , Camundongos , Músculo Esquelético/patologia , Miocárdio/patologia , Nitroimidazóis/farmacologia , Parasitemia , Tripanossomicidas/farmacologia
6.
Int J Cardiol ; 111(1): 104-12, 2006 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-16246441

RESUMO

BACKGROUND: It has been demonstrated that the beta-adrenergic signal transduction system is altered somewhere along its pathway in Trypanosoma cruzi infected hearts and we think that these alterations would differ according to the infection phase and the parasite strain. Their study would be important for the understanding of the disease's pathophysiology. METHODS: In the present work we studied important components of this system in mice hearts infected with T. cruzi, Tulahuen strain and with SGO-Z12 isolate, obtained from a patient of an endemic area, in the acute phase of the infection, determining: the plasma catecholamines levels, the beta-receptors density and affinity as well as their function, the cardiac concentration of cAMP and the cardiac contractility as the physiologic response to the initial stimulus. RESULTS: Plasma catecholamines levels were diminished in both infected groups when compared to the uninfected one (P < 0.01). The receptor's affinity was also diminished (P < 0.05) while their density was augmented only in the SGO-Z12 infected one (P < 0.01). The cAMP levels were higher in both infected groups (P < 0.01), the basal contractile force however increased only in the Tulahuen infected one (P < 0.01) while the response to catecholamines remained unchanged. The hearts infected with the SGO Z12 isolate presented an inferior response to epinephrine (P < 0.05) than the ventricles infected with the Tulahuen strain. CONCLUSIONS: This model represents an important approach to understand the biochemical, physiological and molecular changes in the cardiac beta-adrenergic signalling that clearly begin in the acute phase of Chagas' disease and reveal a clear differentiation in the alterations produced by different parasite strains.


Assuntos
Catecolaminas/sangue , Cardiomiopatia Chagásica/sangue , Epinefrina/sangue , Norepinefrina/sangue , Receptores Adrenérgicos beta/análise , Animais , AMP Cíclico/análise , Coração/fisiopatologia , Humanos , Camundongos , Miocárdio/química , Receptores Adrenérgicos beta/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...